- Home
- IMAB vs GNLX Comparison
IMAB vs GNLX Comparison
Compare IMAB & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMAB
- GNLX
- Stock Information
- Founded
- IMAB 2014
- GNLX 2001
- Country
- IMAB United States
- GNLX United States
- Employees
- IMAB N/A
- GNLX N/A
- Industry
- IMAB Biotechnology: Pharmaceutical Preparations
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- IMAB Health Care
- GNLX Health Care
- Exchange
- IMAB Nasdaq
- GNLX Nasdaq
- Market Cap
- IMAB 83.8M
- GNLX 81.5M
- IPO Year
- IMAB 2020
- GNLX 2023
- Fundamental
- Price
- IMAB $1.07
- GNLX $2.46
- Analyst Decision
- IMAB Strong Buy
- GNLX Strong Buy
- Analyst Count
- IMAB 3
- GNLX 4
- Target Price
- IMAB $8.00
- GNLX $18.25
- AVG Volume (30 Days)
- IMAB 682.1K
- GNLX 80.9K
- Earning Date
- IMAB 03-13-2025
- GNLX 11-14-2024
- Dividend Yield
- IMAB N/A
- GNLX N/A
- EPS Growth
- IMAB N/A
- GNLX N/A
- EPS
- IMAB N/A
- GNLX N/A
- Revenue
- IMAB $3,313,984.00
- GNLX $8,000.00
- Revenue This Year
- IMAB N/A
- GNLX N/A
- Revenue Next Year
- IMAB N/A
- GNLX N/A
- P/E Ratio
- IMAB N/A
- GNLX N/A
- Revenue Growth
- IMAB N/A
- GNLX N/A
- 52 Week Low
- IMAB $0.84
- GNLX $1.60
- 52 Week High
- IMAB $2.08
- GNLX $12.59
- Technical
- Relative Strength Index (RSI)
- IMAB 55.17
- GNLX 48.80
- Support Level
- IMAB $1.00
- GNLX $2.25
- Resistance Level
- IMAB $1.20
- GNLX $2.57
- Average True Range (ATR)
- IMAB 0.12
- GNLX 0.19
- MACD
- IMAB 0.02
- GNLX 0.01
- Stochastic Oscillator
- IMAB 40.97
- GNLX 41.18
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.